CA3005451A1 - Bacteria engineered to reduce hyperphenylalaninemia - Google Patents
Bacteria engineered to reduce hyperphenylalaninemia Download PDFInfo
- Publication number
- CA3005451A1 CA3005451A1 CA3005451A CA3005451A CA3005451A1 CA 3005451 A1 CA3005451 A1 CA 3005451A1 CA 3005451 A CA3005451 A CA 3005451A CA 3005451 A CA3005451 A CA 3005451A CA 3005451 A1 CA3005451 A1 CA 3005451A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- promoter
- encoding
- pal
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 350
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 403
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 377
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 288
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims description 267
- 230000001939 inductive effect Effects 0.000 claims description 196
- 239000001301 oxygen Substances 0.000 claims description 172
- 229910052760 oxygen Inorganic materials 0.000 claims description 172
- 239000013612 plasmid Substances 0.000 claims description 131
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 119
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 116
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 115
- 108010078791 Carrier Proteins Proteins 0.000 claims description 107
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 70
- 230000007613 environmental effect Effects 0.000 claims description 65
- 201000011252 Phenylketonuria Diseases 0.000 claims description 64
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 60
- 101150077062 pal gene Proteins 0.000 claims description 60
- 210000000349 chromosome Anatomy 0.000 claims description 59
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 57
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 57
- 102000004190 Enzymes Human genes 0.000 claims description 56
- 108090000790 Enzymes Proteins 0.000 claims description 56
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 55
- 241000588724 Escherichia coli Species 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 50
- 210000002700 urine Anatomy 0.000 claims description 29
- 239000004098 Tetracycline Substances 0.000 claims description 25
- 239000000411 inducer Substances 0.000 claims description 25
- 229960002180 tetracycline Drugs 0.000 claims description 25
- 229930101283 tetracycline Natural products 0.000 claims description 25
- 235000019364 tetracycline Nutrition 0.000 claims description 25
- 150000003522 tetracyclines Chemical class 0.000 claims description 25
- 210000000813 small intestine Anatomy 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 23
- 230000001965 increasing effect Effects 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 19
- 230000000529 probiotic effect Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000006041 probiotic Substances 0.000 claims description 14
- 235000018291 probiotics Nutrition 0.000 claims description 14
- 235000016709 nutrition Nutrition 0.000 claims description 11
- 241001148064 Photorhabdus luminescens Species 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 241000606125 Bacteroides Species 0.000 claims description 6
- 241000078013 Trichormus variabilis Species 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 241000194036 Lactococcus Species 0.000 claims description 3
- 108090000913 Nitrate Reductases Proteins 0.000 claims description 3
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims description 2
- BOEUHAUGJSOEDZ-UHFFFAOYSA-N 2-amino-5,6,7,8-tetrahydro-1h-pteridin-4-one Chemical compound N1CCNC2=C1C(=O)N=C(N)N2 BOEUHAUGJSOEDZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000018542 Dihydropteridine reductase deficiency Diseases 0.000 claims description 2
- 208000002603 Dopa-responsive dystonia Diseases 0.000 claims description 2
- 101150099538 FNR gene Proteins 0.000 claims description 2
- 208000021199 Hyperphenylalaninemia due to tetrahydrobiopterin deficiency Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims description 2
- 208000026770 mild hyperphenylalaninemia Diseases 0.000 claims description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 229960005190 phenylalanine Drugs 0.000 description 285
- 230000014509 gene expression Effects 0.000 description 259
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 152
- 108090000765 processed proteins & peptides Proteins 0.000 description 112
- 102000004196 processed proteins & peptides Human genes 0.000 description 84
- 229920001184 polypeptide Polymers 0.000 description 73
- 101150081344 PAL3 gene Proteins 0.000 description 71
- 238000001727 in vivo Methods 0.000 description 70
- 101150080283 RIM8 gene Proteins 0.000 description 66
- 230000002103 transcriptional effect Effects 0.000 description 64
- 210000004369 blood Anatomy 0.000 description 62
- 239000008280 blood Substances 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 61
- 230000001580 bacterial effect Effects 0.000 description 57
- 229940088598 enzyme Drugs 0.000 description 55
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 54
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 53
- 230000000670 limiting effect Effects 0.000 description 51
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 description 46
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 238000002347 injection Methods 0.000 description 42
- 239000007924 injection Substances 0.000 description 42
- -1 "in vivo" activation Chemical compound 0.000 description 40
- 230000001105 regulatory effect Effects 0.000 description 39
- 230000027455 binding Effects 0.000 description 36
- 210000003578 bacterial chromosome Anatomy 0.000 description 35
- 239000002207 metabolite Substances 0.000 description 35
- 230000001419 dependent effect Effects 0.000 description 34
- 101150035123 pme gene Proteins 0.000 description 34
- 238000013518 transcription Methods 0.000 description 34
- 230000035897 transcription Effects 0.000 description 34
- 229940024606 amino acid Drugs 0.000 description 33
- 101100352026 Escherichia coli (strain K12) pheP gene Proteins 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 32
- 230000008520 organization Effects 0.000 description 32
- 230000006698 induction Effects 0.000 description 28
- 238000003780 insertion Methods 0.000 description 28
- 230000037431 insertion Effects 0.000 description 28
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 27
- 101150101950 pheP gene Proteins 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 26
- 230000028327 secretion Effects 0.000 description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- 241000894007 species Species 0.000 description 24
- 108700012359 toxins Proteins 0.000 description 24
- 230000015556 catabolic process Effects 0.000 description 22
- 239000003053 toxin Substances 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 21
- 230000012010 growth Effects 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 231100000765 toxin Toxicity 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 230000001147 anti-toxic effect Effects 0.000 description 20
- 230000004060 metabolic process Effects 0.000 description 20
- 244000005700 microbiome Species 0.000 description 20
- 108010091086 Recombinases Proteins 0.000 description 19
- 102000018120 Recombinases Human genes 0.000 description 19
- 230000002759 chromosomal effect Effects 0.000 description 19
- 101150066555 lacZ gene Proteins 0.000 description 19
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 19
- 108091023040 Transcription factor Proteins 0.000 description 18
- 102000040945 Transcription factor Human genes 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 16
- 150000007523 nucleic acids Chemical group 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 101150011371 dapA gene Proteins 0.000 description 15
- 238000010586 diagram Methods 0.000 description 15
- 101150072314 thyA gene Proteins 0.000 description 15
- 230000032258 transport Effects 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 150000008575 L-amino acids Chemical class 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 12
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 12
- 241000588770 Proteus mirabilis Species 0.000 description 12
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 229940023064 escherichia coli Drugs 0.000 description 12
- 238000003304 gavage Methods 0.000 description 12
- 238000010172 mouse model Methods 0.000 description 12
- 101150036331 pah gene Proteins 0.000 description 12
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 108010074051 C-Reactive Protein Proteins 0.000 description 10
- 102100032752 C-reactive protein Human genes 0.000 description 10
- 101710092888 Integrator complex subunit 5 Proteins 0.000 description 10
- 101150072055 PAL1 gene Proteins 0.000 description 10
- 241000588769 Proteus <enterobacteria> Species 0.000 description 10
- 101100192827 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PXA1 gene Proteins 0.000 description 10
- 244000052616 bacterial pathogen Species 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 101150010999 aroP gene Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 210000001322 periplasm Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 8
- 108010048816 AraC Transcription Factor Proteins 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108091026922 FnrS RNA Proteins 0.000 description 8
- 101710137500 T7 RNA polymerase Proteins 0.000 description 8
- DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 8
- 210000002429 large intestine Anatomy 0.000 description 8
- 101150076563 malP gene Proteins 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 108700010070 Codon Usage Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 229940114081 cinnamate Drugs 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 101150038370 yicS gene Proteins 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 102100039131 Integrator complex subunit 5 Human genes 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 101150044616 araC gene Proteins 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 101150034943 nepI gene Proteins 0.000 description 6
- 238000000782 polymeric membrane extraction Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108050005273 Amino acid transporters Proteins 0.000 description 5
- 102000034263 Amino acid transporters Human genes 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 102000003929 Transaminases Human genes 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000003570 air Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000036316 preload Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 229960004441 tyrosine Drugs 0.000 description 5
- 101150096946 ydfZ gene Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- VOXXWSYKYCBWHO-UHFFFAOYSA-M 3-phenyllactate Chemical compound [O-]C(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-M 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 4
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010010256 Dietary Proteins Proteins 0.000 description 4
- 102000015781 Dietary Proteins Human genes 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
- 102000004317 Lyases Human genes 0.000 description 4
- 108090000856 Lyases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000588771 Morganella <proteobacterium> Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 108030006586 Phenylalanine dehydrogenases Proteins 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 241000588768 Providencia Species 0.000 description 4
- 108010069584 Type III Secretion Systems Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 235000021245 dietary protein Nutrition 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 101150044129 nirB gene Proteins 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960004617 sapropterin Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091006106 transcriptional activators Proteins 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 3
- 101100203377 Bacillus subtilis (strain 168) slp gene Proteins 0.000 description 3
- 241000606124 Bacteroides fragilis Species 0.000 description 3
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 3
- 241000193171 Clostridium butyricum Species 0.000 description 3
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 3
- 229930182832 D-phenylalanine Natural products 0.000 description 3
- 101100242529 Drosophila melanogaster Pal2 gene Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 101150012565 LRIT1 gene Proteins 0.000 description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 101100477497 Mus musculus Shcbp1 gene Proteins 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 244000057717 Streptococcus lactis Species 0.000 description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000447 dimerizing effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 229940003703 kuvan Drugs 0.000 description 3
- 101150109249 lacI gene Proteins 0.000 description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 238000007833 oxidative deamination reaction Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 229960002181 saccharomyces boulardii Drugs 0.000 description 3
- RKSUYBCOVNCALL-NTVURLEBSA-N sapropterin dihydrochloride Chemical compound Cl.Cl.N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 RKSUYBCOVNCALL-NTVURLEBSA-N 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 101150061166 tetR gene Proteins 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 2
- XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 description 2
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 101100378572 Escherichia coli (strain K12) agaI gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100024977 Glutamine-tRNA ligase Human genes 0.000 description 2
- 101100082540 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pcp gene Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 101150108784 INSB gene Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 2
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 241000219470 Mirabilis Species 0.000 description 2
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 2
- 241001148062 Photorhabdus Species 0.000 description 2
- 241000350158 Prioria balsamifera Species 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 2
- 241000221523 Rhodotorula toruloides Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 108010073429 Type V Secretion Systems Proteins 0.000 description 2
- 108010046179 Type VI Secretion Systems Proteins 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- DLRVVLDZNNYCBX-CAPXFGMSSA-N allolactose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)O1 DLRVVLDZNNYCBX-CAPXFGMSSA-N 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 230000009604 anaerobic growth Effects 0.000 description 2
- 210000002255 anal canal Anatomy 0.000 description 2
- 108700003859 araC Genes Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 101150018266 degP gene Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 101150094936 fliD gene Proteins 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108010051239 glutaminyl-tRNA synthetase Proteins 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 101150074251 lpp gene Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108010038980 phenylalanine aminotransferase Proteins 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 101150061689 rsmI gene Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 101150061964 tolA gene Proteins 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 101100326957 Bacillus subtilis (strain 168) catD gene Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 101710154303 Cyclic AMP receptor protein Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 101100337717 Escherichia coli (strain K12) grcA gene Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 1
- 101100495405 Escherichia coli cvaC gene Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101100293613 Haloferax mediterranei (strain ATCC 33500 / DSM 1411 / JCM 8866 / NBRC 14739 / NCIMB 2177 / R-4) nasB gene Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000000481 Maternal phenylketonuria Diseases 0.000 description 1
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 1
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700006385 OmpF Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 101710165016 Phenylalanine-specific permease Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000018819 Protein Translocation Systems Human genes 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589755 Pseudomonas mendocina Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000589615 Pseudomonas syringae Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101100241087 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) nrtP gene Proteins 0.000 description 1
- 101100132804 Thermus thermophilus narK1 gene Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108010058153 Twin-Arginine-Translocation System Proteins 0.000 description 1
- 108010064721 Type I Secretion Systems Proteins 0.000 description 1
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 1
- 108010050970 Type VII Secretion Systems Proteins 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 101150061301 ahpF gene Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002529 anti-mitochondrial effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000009015 carbon catabolite repression of transcription Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 108091006116 chimeric peptides Proteins 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 101150083941 degS gene Proteins 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 101150077334 focA gene Proteins 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 101150107068 gsiB gene Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 101150041770 hlyE gene Proteins 0.000 description 1
- 101150099805 htpG gene Proteins 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010060845 lactose permease Proteins 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- XEFNBUBDJCJOGM-OUJCMCIWSA-N n-[1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 XEFNBUBDJCJOGM-OUJCMCIWSA-N 0.000 description 1
- 101150062306 narK gene Proteins 0.000 description 1
- 101150037810 narT gene Proteins 0.000 description 1
- 101150056725 narX gene Proteins 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 101150106215 ndh gene Proteins 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 101150050698 nlpI gene Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 101150021871 norC gene Proteins 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 101150110245 ompC gene Proteins 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 101150008884 osmY gene Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 101150038927 pdhR gene Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 108010078226 phenylalanine oxidase Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 101150004519 pilC gene Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 101150033014 rhtB gene Proteins 0.000 description 1
- 101150094644 rhtC gene Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 101150112274 ssb gene Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 101150019205 tdcD gene Proteins 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256052P | 2015-11-16 | 2015-11-16 | |
| US62/256,052 | 2015-11-16 | ||
| USPCT/US2016/032562 | 2016-05-13 | ||
| PCT/US2016/032562 WO2016183531A1 (en) | 2015-05-13 | 2016-05-13 | Bacteria engineered to reduce hyperphenylalaninemia |
| PCT/US2016/062369 WO2017087580A1 (en) | 2015-11-16 | 2016-11-16 | Bacteria engineered to reduce hyperphenylalaninemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3005451A1 true CA3005451A1 (en) | 2017-05-26 |
Family
ID=58717781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3005451A Pending CA3005451A1 (en) | 2015-11-16 | 2016-11-16 | Bacteria engineered to reduce hyperphenylalaninemia |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11618894B2 (enExample) |
| EP (2) | EP3377518B1 (enExample) |
| JP (4) | JP6993970B2 (enExample) |
| AU (3) | AU2016356684C1 (enExample) |
| CA (1) | CA3005451A1 (enExample) |
| ES (1) | ES2925049T3 (enExample) |
| PL (1) | PL3377518T3 (enExample) |
| WO (1) | WO2017087580A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022121968A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海陶宇晟生物技术有限责任公司 | 具有降解苯丙氨酸能力的工程益生菌 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10610546B2 (en) | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| EP3377518B1 (en) * | 2015-11-16 | 2022-04-13 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| AU2018290278B2 (en) | 2017-06-21 | 2022-12-15 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| KR20220003030A (ko) | 2019-04-29 | 2022-01-07 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수 |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| WO2021009091A1 (en) * | 2019-07-15 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating cardiac dysfunction |
| CN110643585B (zh) * | 2019-11-08 | 2021-09-03 | 江南大学 | 一种利用氨基酸脱氨酶生产α-酮-β-甲基正戊酸的方法 |
| CN113493796B (zh) * | 2020-03-18 | 2023-05-30 | 苏州优信合生技术有限公司 | 苯丙酮尿症治疗用益生菌工程菌株的构建方法与应用 |
| BR112022018571A2 (pt) | 2020-03-20 | 2022-11-01 | Synlogic Operating Co Inc | Microrganismos manipulados para reduzir a hiperfenilalaninemia |
| CN113755516A (zh) * | 2020-06-05 | 2021-12-07 | 中国医学科学院药物研究所 | 工程粪肠球菌在治疗苯丙酮尿症药物中的应用 |
| US20220031771A1 (en) * | 2020-07-31 | 2022-02-03 | Iowa State University Research Foundation, Inc. | Microencapsulated and chromosome integrated compositions for l-dopa microbiome therapy |
| AU2021393455A1 (en) | 2020-12-02 | 2023-06-29 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| CN112662607A (zh) * | 2021-01-07 | 2021-04-16 | 上海陶宇晟生物技术有限责任公司 | 具备表面展示苯丙氨酸解氨酶的工程益生菌 |
| WO2023044479A1 (en) * | 2021-09-17 | 2023-03-23 | Synlogic Operating Company, Inc. | Methods for reducing hyperphenylalaninemia |
| CN113969292B (zh) * | 2021-11-15 | 2023-07-07 | 山东第一医科大学(山东省医学科学院) | 治疗苯丙酮尿症的工程益生菌及其构建方法与应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| CN1154845A (zh) * | 1996-09-09 | 1997-07-23 | 首都医学院附属北京红十字朝阳医院 | 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂 |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| JP4347575B2 (ja) | 2001-05-03 | 2009-10-21 | アクトジェニックス・エヌブイ | 自己自制ラクトコッカス（Ｌｏｃｔｏｃｏｃｃｕｓ）株 |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| JP4452914B2 (ja) | 2003-09-08 | 2010-04-21 | 味の素株式会社 | 新規トランスポータタンパク質 |
| CA2559760A1 (en) * | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
| GB0501540D0 (en) | 2005-01-25 | 2005-03-02 | Univ Leeds | Controlled production and delivery of biologically active agents by gut bacteria |
| EP1869174B1 (en) * | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| CA2653967A1 (en) | 2006-06-02 | 2008-10-02 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
| US20100297249A1 (en) * | 2007-07-05 | 2010-11-25 | North-West University | Enhancement of the efficacy of therapeutic proteins |
| CN101586111B (zh) | 2008-05-22 | 2012-03-07 | 北京三元基因工程有限公司 | 一种活性乳酸乳球菌制品的制备方法 |
| EP2344626B1 (en) | 2008-09-29 | 2017-03-29 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
| WO2011106874A1 (en) | 2010-03-02 | 2011-09-09 | Functional Technologies Corp. | Functional enhancement of microorganisms to minimize production of acrylamide |
| US8129170B1 (en) | 2010-12-06 | 2012-03-06 | E.I. Du Pont De Nemours And Company | Recombinant bacteria having the ability to metabolize sucrose |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
| FR2990699B1 (fr) | 2012-05-21 | 2016-02-05 | Agronomique Inst Nat Rech | Cassettes d'expression procaryotes regulees par le stress |
| CN104487581B (zh) * | 2012-06-22 | 2021-05-28 | 菲特吉恩公司 | 用于苯乙烯合成的酶和方法 |
| CA2880620A1 (en) | 2012-07-27 | 2014-01-30 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| US20150246085A1 (en) | 2012-11-01 | 2015-09-03 | The Sydney Children's Hospital Network (Randwick & Westmead) | Genetically-Modified Probiotic for Treatment of Phenylketonuria |
| CA2894710A1 (en) | 2012-12-13 | 2014-06-19 | Massachusetts Institute Of Technology | Recombinase-based logic and memory systems |
| WO2014138324A1 (en) | 2013-03-07 | 2014-09-12 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
| US9688967B2 (en) * | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| US10610546B2 (en) | 2015-05-13 | 2020-04-07 | Synlogic Operating Company Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| EP3294757B1 (en) * | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| EP3307870B1 (en) * | 2015-06-10 | 2023-08-02 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
| WO2016210373A2 (en) | 2015-06-24 | 2016-12-29 | Synlogic, Inc. | Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof |
| US20170216370A1 (en) * | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
| EP3377518B1 (en) * | 2015-11-16 | 2022-04-13 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| WO2018187552A1 (en) * | 2017-04-05 | 2018-10-11 | University Of Massachusetts | Minigene therapy |
| SK289101B6 (sk) * | 2020-12-17 | 2023-08-09 | Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia | Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie |
-
2016
- 2016-11-16 EP EP16810138.4A patent/EP3377518B1/en active Active
- 2016-11-16 JP JP2018526505A patent/JP6993970B2/ja active Active
- 2016-11-16 WO PCT/US2016/062369 patent/WO2017087580A1/en not_active Ceased
- 2016-11-16 PL PL16810138.4T patent/PL3377518T3/pl unknown
- 2016-11-16 EP EP22167588.7A patent/EP4095150A1/en active Pending
- 2016-11-16 AU AU2016356684A patent/AU2016356684C1/en active Active
- 2016-11-16 CA CA3005451A patent/CA3005451A1/en active Pending
- 2016-11-16 US US15/775,936 patent/US11618894B2/en active Active
- 2016-11-16 ES ES16810138T patent/ES2925049T3/es active Active
-
2021
- 2021-12-10 JP JP2021200761A patent/JP7245312B2/ja active Active
-
2022
- 2022-03-16 AU AU2022201838A patent/AU2022201838B2/en active Active
- 2022-12-19 US US18/068,004 patent/US20240076645A1/en active Pending
-
2023
- 2023-03-10 JP JP2023037499A patent/JP7494345B2/ja active Active
-
2024
- 2024-05-22 JP JP2024083082A patent/JP2024112925A/ja active Pending
-
2025
- 2025-04-17 AU AU2025202726A patent/AU2025202726A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022121968A1 (zh) * | 2020-12-11 | 2022-06-16 | 上海陶宇晟生物技术有限责任公司 | 具有降解苯丙氨酸能力的工程益生菌 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016356684C1 (en) | 2022-11-10 |
| US11618894B2 (en) | 2023-04-04 |
| JP7245312B2 (ja) | 2023-03-23 |
| AU2016356684A1 (en) | 2018-05-31 |
| EP3377518A1 (en) | 2018-09-26 |
| AU2022201838A1 (en) | 2022-04-07 |
| EP3377518B1 (en) | 2022-04-13 |
| AU2025202726A1 (en) | 2025-05-08 |
| JP7494345B2 (ja) | 2024-06-03 |
| WO2017087580A1 (en) | 2017-05-26 |
| JP2023085294A (ja) | 2023-06-20 |
| EP4095150A1 (en) | 2022-11-30 |
| ES2925049T3 (es) | 2022-10-13 |
| JP2018535678A (ja) | 2018-12-06 |
| PL3377518T3 (pl) | 2022-09-26 |
| US20180320161A1 (en) | 2018-11-08 |
| US20240076645A1 (en) | 2024-03-07 |
| AU2016356684B2 (en) | 2021-12-16 |
| JP6993970B2 (ja) | 2022-02-15 |
| AU2022201838B2 (en) | 2025-01-23 |
| JP2022046527A (ja) | 2022-03-23 |
| JP2024112925A (ja) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021212141B2 (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| US20240076645A1 (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| JP2018535678A5 (enExample) | ||
| WO2017123592A1 (en) | Bacteria engineered to treat disorders associated with bile salts | |
| US20230090705A1 (en) | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | |
| HK40085223A (en) | Bacteria engineered to reduce hyperphenylalaninemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |
|
| EEER | Examination request |
Effective date: 20211112 |